Rifampicin treatment
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
CYP3A4 Induction
Conditions
CYP3A4 Induction
Trial Timeline
May 1, 2011 → Jul 1, 2011
NCT ID
NCT01340456About Rifampicin treatment
Rifampicin treatment is a pre-clinical stage product being developed by AstraZeneca for CYP3A4 Induction. The current trial status is completed. This product is registered under clinical trial identifier NCT01340456. Target conditions include CYP3A4 Induction.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01340456 | Pre-clinical | Completed |
Competing Products
1 competing product in CYP3A4 Induction
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Sativex and rifampicin + Sativex and rifampicin + Sativex and ketoconazole + Sativex and ketoconazole + Sativex and omeprazole + Sativex and omeprazole | Jazz Pharmaceuticals | Phase 1 | 30 |